Top View
- Rasagiline NDC 0378- -93 Dispense in a Tight, Light-Resistant Mesylate Equivalent to 0.5 Mg 1270 Container As Defined in the USP of Rasagiline
- Comtan, INN-Entacapone
- Parkinson's Disease with End-Of-Dose Motor Fluctuations: Opicapone
- Carbidopa-Levodopa-Entacapone (Stalevo)
- Parkinson's Treatment “Tips & Pearls”
- PSP: Some Answers
- Levodopa/Carbidopa/Entacapone Orion, INN-Levodopa, Carbidopa
- Appendix B - Product Name Sorted by Applicant
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Safinamide (Xadago) Reference Number: ERX.NPA.45 Effective Date: 09.01.17 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
- PUBLIC SUMMARY DOCUMENT Product: RASAGILINE, Tablet, 1 Mg, Azilect® Sponsor: Lundbeck Australia Pty Ltd Date of PBAC Consideration: July 2011
- Second Quarter 2019 Update: Changes to the Highmark Drug Formularies
- Therapeutic Drug Class
- ENTAPONE 1. Product Name 2. Qualitative and Quantitative
- Opioid Codrugs for Pain Management
- Parkinson's Disease Medications
- Levodopa/Carbidopa/Entacapone Orion, INN-Levodopa, Carbidopa
- Practical Guidelines for Management of Parkinson Disease
- Antiparkinson's Agents
- Relationship Between 3-O-Methyldopa and the Clinical Effects of Entacapone in Advanced Parkinson’S Disease
- Safinamide Improves Non-Motor Symptoms Burden In
- Medicaid Health Plan Common Formulary
- Opicapone ®▼ (Ongentys )
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Overview of Parkinson's Disease Treatment Options
- Safinamide – Benefit Assessment According to §35A Social Code Book V1
- Comtan, Film Coated Tablet
- Entacapone Is Beneficial in Both Fluctuating and Non-Fluctuating
- Levodopa, Carbidopa, and Entacapone | Memorial Sloan
- Entacapone-Containing Products – Safety Update
- Bordeaux JJF Pharmacological Treatment of Parkinson's Disease
- A Treatment Guide to Parkinson's Disease
- Medical Management of Parkinson's Disease
- Medical Necessity Criteria for Pharmacy Edits, 5.01.605
- COMT Inhibitors
- Levodopa, Carbidopa, Entacapone > Printer-Friendly PDF
- PD Medications: Managing Side Effects Led By
- Carbidopa, Entacapone and Levodopa
- Risk Assessment and Risk Mitigation Review(S)
- Movement Disorders Parkinson's Disease
- Ongentys) Reference Number: ERX.NPA.144 Effective Date: 09.01.20 Last Review Date: 08.20 Line of Business: Commercial, Medicaid Revision Log
- Comtan (Entacapone Tablets Label
- Safinamide (Xadago) Reference Number: PA.CP.PMN.113 Effective Date: 04.17.19 Last Review Date: 04.19 Revision Log
- CVS Caremark® Value Formulary Effective As of 07/01/2021
- Medications for Insomnia
- Opicapone: from Preclinical Data to Real-World Evidence
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Supplementary Material
- Drug Discovery for Neurological Disorders: a Focus on Bioassay Development
- Increased Dose of Carbidopa with Levodopa and Entacapone Improves “Off” Time in a Randomized Trial
- Dopamine Agonists, MAO-B Inhibitors, and More
- COMT Inhibitors
- Numient, INN-Levodopa/Carbidopa
- CP.PMN.113 Safinamide (Xadago)
- Preferred Drug List
- Download Leaflet View the Patient Leaflet in PDF Format
- Pharmaceutical Impurities and Primary Reference Standards Catalogue